TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1333071

Group type: EXPERIMENTAL
Intervention: 71.5 Gy in 52 fractions of 1.375 Gy given twice a day (hyperfractionated radiotherapy)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 65 Gy in 26 fractions of 2.5 Gy each (conventional radiotherapy)
Number of subjects: 36
Study: 3882307

Group type: EXPERIMENTAL
Intervention: Guanfacine, 1 to 3 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clonidine, 0.1 to 0.3 mg twice a day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clonidine withdrawal
Number of subjects: 42

Group type: COMPARATOR
Intervention: Guanfacine withdrawal
Number of subjects: 42
Study: 31271210

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy for insomnia (bCBTi)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment-as-usual for MDD and/or PTSD
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: bCBTi
Number of subjects: 54
Study: 28751176

Group type: EXPERIMENTAL
Intervention: Basic reminder condition
Number of subjects: 46581

Group type: EXPERIMENTAL
Intervention: Prediction condition
Number of subjects: 46581

Group type: EXPERIMENTAL
Intervention: Commitment condition
Number of subjects: 46581

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 46581
Study: 26184510

Group type: EXPERIMENTAL
Intervention: CKD stage 3B-5
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: eGFR <45 ml/min/1.73 m(2)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: CKD stage 2-3
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: eGFR loss
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: CKD equations (CG/BSA, BIS1, LM-rev)
Number of subjects: 1011
Study: 25052243

Group type: EXPERIMENTAL
Intervention: MDMA (75 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22210240

Group type: EXPERIMENTAL
Intervention: Baseline HADS‐A score
Number of subjects: 137
Study: 19534770

Group type: EXPERIMENTAL
Intervention: Novel rehabilitation strategy consisting of an initial home exercise programme followed by higher intensity outpatient exercise classes.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual rehabilitative care as provided by the hospital or recommended by the orthopaedic surgeon.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Novel rehabilitation strategy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual rehabilitative care
Number of subjects: 600
Study: 17288694

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg QD
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 684
Study: 15354280

Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg twice daily
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg and 6 mg
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 1348
Study: 12060615

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (AIT) with tumor-associated lymphocytes (TALs) plus low-dose cisplatinum/5-fluorouracil chemotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 44
Study: 10102433

Group type: EXPERIMENTAL
Intervention: Natalizumab (0.03 to 3.0 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Natalizumab (1- or 3-mg/kg IV dose)
Number of subjects: 28
Study: 7480850

Group type: EXPERIMENTAL
Intervention: Parent training program (10-week duration)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 46
Study: 2263920

Group type: EXPERIMENTAL
Intervention: Ultrasound (A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo ultrasound (B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No therapeutic intervention (C)
Number of subjects: 18
Study: 7459895

Group type: EXPERIMENTAL
Intervention: Single large dose of misonidazole
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multiple smaller doses of misonidazole
Number of subjects: 21

Group type: COMPARATOR
Intervention: Irradiation only (Control)
Number of subjects: 21
Study: 6677075

Group type: EXPERIMENTAL
Intervention: Stagefright anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotonous concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 0
Study: 31842921

Group type: EXPERIMENTAL
Intervention: Bone-marrow autologous mesenchymal stem cells (MSC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: P-PRP
Number of subjects: 20
Study: 30393990

Group type: EXPERIMENTAL
Intervention: Universal testing with universal leucoreduction
Number of subjects: 10000000000

Group type: EXPERIMENTAL
Intervention: Testing only first-time donors with universal leucoreduction
Number of subjects: 10000000000

Group type: EXPERIMENTAL
Intervention: No testing with universal leucoreduction
Number of subjects: 10000000000

Group type: EXPERIMENTAL
Intervention: Efficacy of leucoreduction
Number of subjects: 10000000000
Study: 25664595

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (TUDCA) 1 g twice daily for 54 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TUDCA
Number of subjects: 34
Study: 24944242

Group type: EXPERIMENTAL
Intervention: V2R agonist (0.2 mg desmopressin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: V2R antagonist (30 mg tolvaptan)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All conditions (including placebo)
Number of subjects: 10
Study: 22113708

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg day(‐1)) for 1 month
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no vitamin E)
Number of subjects: 50
Study: 20711481

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 18519471

Group type: EXPERIMENTAL
Intervention: Constantly low sucrose intake (lowest 10%)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Average sucrose intake (80%)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Constantly high sucrose intake (highest 10%)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Low and average sucrose intake groups
Number of subjects: 543
Study: 15084928

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic donor nephrectomy (HALDN)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Pure retroperitoneoscopic donor nephrectomy (RLDN)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both HALDN and RLDN
Number of subjects: 59
Study: 11698565

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 5 years)
Number of subjects: 11064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11064
Study: 9219046

Group type: EXPERIMENTAL
Intervention: Clozapine (mean dose of 166 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorpromazine (mean dose of 310 mg/day)
Number of subjects: 30
Study: 7524888

Group type: EXPERIMENTAL
Intervention: Busulphan (1 mg/kg orally QID days -7 to -4) and cyclophosphamide (60 mg/kg IV days -3 and -2) chemotherapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Post-transplant G-CSF
Number of subjects: 69
Study: 3109575

Group type: EXPERIMENTAL
Intervention: Attempted induction of labour (group 1)
Number of subjects: 409

Group type: COMPARATOR
Intervention: No intervention (group 2)
Number of subjects: 409
Study: 29569449

Group type: EXPERIMENTAL
Intervention: Zirconia crown placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-restorative therapy
Number of subjects: 40
Study: 29231295

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zusanli (ST 36) and Feishu (BL 13) applied 30 min before the operation till the end of the operation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 80
Study: 24148208

Group type: EXPERIMENTAL
Intervention: 10-week group self-management intervention addressing proactive coping strategies
Number of subjects: 106

Group type: COMPARATOR
Intervention: group education intervention
Number of subjects: 106
Study: 22492213

Group type: EXPERIMENTAL
Intervention: DaTscan imaging
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (no imaging)
Number of subjects: 273
Study: 20972912

Group type: EXPERIMENTAL
Intervention: Group CBT delivered in a psychiatric setting for 10 weeks
Number of subjects: 24
Study: 17517798

Group type: EXPERIMENTAL
Intervention: Coronary stenting in patients with mild to moderate CKD
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Coronary stenting in patients without CKD
Number of subjects: 1228
Study: 15677778

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once daily and lisinopril 20 mg once daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lisinopril 40 mg once daily
Number of subjects: 75
Study: 12216507

Group type: EXPERIMENTAL
Intervention: Preoperative ketamine (0.15 mg/Kg i.v.)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Postoperative ketamine (0.15 mg/Kg i.v.)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9640215

Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Tumorectomy plus radiotherapy
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 1036
Study: 8018443

Group type: EXPERIMENTAL
Intervention: 6-hour small-group intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Written materials about AIDS
Number of subjects: 148
Study: 2730122

Group type: EXPERIMENTAL
Intervention: Heated, water filled mattress kept at 37 degrees C (n = 28)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Air heated incubators with a mean air temperature of 35 degrees C (n = 32)
Number of subjects: 60
Study: 5662989

Group type: EXPERIMENTAL
Intervention: Fried onions (60 g)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Boiled onions (60 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fat-enriched breakfast without onions
Number of subjects: 22
Study: 30633744

Group type: EXPERIMENTAL
Intervention: Culturally‐Tailored Smoking Cessation plus Adherence Enhancement (CT+AE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Culturally‐Tailored Smoking Cessation (CTSC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 25
Study: 28062272

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Risk Score (CRS)
Number of subjects: 0
Study: 27138185

Group type: EXPERIMENTAL
Intervention: ETC-1002 120 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: ETC-1002 180 mg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 22713361

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23048056

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-dose clopidogrel (150 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CYP2C19*2 noncarriers (high-dose clopidogrel)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CYP2C19*2 carriers (high-dose clopidogrel)
Number of subjects: 32
Study: 19745764

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg oral once daily
Number of subjects: 64
Study: 17513627

Group type: EXPERIMENTAL
Intervention: PEEP of 6-cm H2O
Number of subjects: 46

Group type: COMPARATOR
Intervention: PEEP of 3-cm H2O
Number of subjects: 46
Study: 15386325

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard laparoscopic surgery
Number of subjects: 0
Study: 11263473

Group type: EXPERIMENTAL
Intervention: rhIGF-I (20 microg/kg s.c. at -180 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hCRH (2.0 microg/kg i.v. at 0 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HEX (2.0 microg/kg i.v. at 0 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: rhIGF-I
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HEX
Number of subjects: 6
Study: 10459091

Group type: EXPERIMENTAL
Intervention: Warmed normal saline solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Room temperature saline solution
Number of subjects: 40
Study: 8682087

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment in autoreactive forms of myocarditis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperimmunoglobulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunomodulating factors (e.g., ribaverin, interleukins, interferons)
Number of subjects: 0
Study: 1967500

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.75 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 345534

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside ointment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Idoxuridine ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31103365

Group type: EXPERIMENTAL
Intervention: GEN-003 (60 µg antigen/50 µg M2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: GEN-003 (60 µg/75 µg M2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 28969328

Group type: EXPERIMENTAL
Intervention: Viscoelastometry guided fresh frozen plasma (FFP) infusion
Number of subjects: 605
Study: 25533539

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) titrated to effect, starting at 4.5 g/night and adjusted based on clinical response, for a duration of 12 weeks.
Number of subjects: 202
Study: 23461778

Group type: EXPERIMENTAL
Intervention: Altemeier's procedure
Number of subjects: 293

Group type: COMPARATOR
Intervention: Delorme's procedure
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Resection rectopexy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Suture rectopexy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Perineal surgery
Number of subjects: 293

Group type: COMPARATOR
Intervention: Abdominal surgery
Number of subjects: 293
Study: 21338492

Group type: EXPERIMENTAL
Intervention: Ultrasound guided fascia iliaca block using levobupivacaine, plus spinal anaesthesia with hyperbaric bupivacaine containing no morphine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham ultrasound guided fascia iliaca block performed with sterile saline, and spinal anaesthesia containing hyperbaric bupivacaine and 0.1 mg of spinal morphine
Number of subjects: 108
Study: 19470062

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% and salicylic acid 5% for the first 7 days, followed by mometasone furoate 0.1% for 14 days
Number of subjects: 360

Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% for 21 consecutive days
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% and salicylic acid 5% followed by mometasone furoate 0.1%
Number of subjects: 360
Study: 16988939

Group type: EXPERIMENTAL
Intervention: Interpersonal counseling (IPC), 1 to 6 weekly sessions, telephone-administered
Number of subjects: 17
Study: 15188834

Group type: EXPERIMENTAL
Intervention: Basal FSH levels
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate challenge test (CCCT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist stimulation test (GAST)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound for ovarian volume measurements
Number of subjects: 144
Study: 11879297

Group type: EXPERIMENTAL
Intervention: Mammography screening programs for elderly women
Number of subjects: 0
Study: 10195048

Group type: EXPERIMENTAL
Intervention: Peer led intervention delivered by trained volunteers aged 16-17 years
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual teacher led sex education
Number of subjects: 500
Study: 1637758

Group type: EXPERIMENTAL
Intervention: Sweeping of the membranes
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 6478137

Group type: EXPERIMENTAL
Intervention: Direct cervical puncture technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lumbar puncture with run-up technique
Number of subjects: 300
Study: 31515397

Group type: EXPERIMENTAL
Intervention: Biologic therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29753356

Group type: EXPERIMENTAL
Intervention: Bring Your Own Device (BYOD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Site device
Number of subjects: 155

Group type: COMPARATOR
Intervention: Paper
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: BYOD
Number of subjects: 155
Study: 27120317

Group type: EXPERIMENTAL
Intervention: Standalone computer-delivered brief intervention (BI)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Therapist-delivered brief intervention (BI)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 836
Study: 24084071

Group type: EXPERIMENTAL
Intervention: LABA step-up therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LTRA step-up therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICS step-up therapy
Number of subjects: 0
Study: 21113076

Group type: EXPERIMENTAL
Intervention: e‐Chasqui web‐based information system (intervention group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Paper-based system (control group)
Number of subjects: 78
Study: 19404073

Group type: EXPERIMENTAL
Intervention: Stoma patients (temporary or permanent)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Non-stoma patients
Number of subjects: 186
Study: 17515847

Group type: EXPERIMENTAL
Intervention: Fermented formula (FF) with Bifidobacterium breve C50 and Streptococcus thermophilus 065
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 90
Study: 15106502

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 11696139

Group type: EXPERIMENTAL
Intervention: Standard insertion technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Partially inflated cuff insertion technique
Number of subjects: 80
Study: 9738173

Group type: EXPERIMENTAL
Intervention: Palivizumab (15 mg/kg)
Number of subjects: 1502
Study: 8731298

Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH) 160 UaXa IC/kg/day (group IA)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH) 320 UaXa IC/kg/day (group IB)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Intravenous non-fractioned heparin (NFH) 100UI/kg (bolus), followed by 1000UI/h
Number of subjects: 314
Study: 2663639

Group type: EXPERIMENTAL
Intervention: Othmer and DeSouza's screening index
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DIS-derived screening index
Number of subjects: 100
Study: 893685

Group type: EXPERIMENTAL
Intervention: Schizophrenic subtypes (process, reactive, paranoid, nonparanoid, long‐ and short‐hospitalization, long‐ and short‐length of illness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matched groups of schizophrenic subtypes
Number of subjects: 0
Study: 31125163

Group type: EXPERIMENTAL
Intervention: Intervention: Protocol for early mobilization in ICUs.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control: Standard care without the protocol for early mobilization.
Number of subjects: 272
Study: 30771641

Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 78
Study: 26911485

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 60)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (n = 67)
Number of subjects: 127
Study: 26269615

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.5 mg/kg/dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg/kg/dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 5.0 mg/kg/dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 23615578

Group type: EXPERIMENTAL
Intervention: Verbal working memory training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 36
Study: 21995648

Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate sodium (CMS‐Na) 2.5 mg/kg as colistin activity, 75,000 IU/kg, twice daily repeat doses
Number of subjects: 22

Group type: COMPARATOR
Intervention: Colistin methanesulfonate sodium (CMS‐Na) 2.5 mg/kg as colistin activity, 75,000 IU/kg, single dose
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate sodium (CMS‐Na)
Number of subjects: 22
Study: 19154837

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2max) estimated from a modified submaximal Astrand bicycle test
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Levels of activity during leisure time and work/household
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Fear avoidance model variables
Number of subjects: 223
Study: 17034280

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation via an ECG electrode
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Manual stimulation via an acupuncture needle
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimulation via an acupuncture needle
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control location (NP)
Number of subjects: 15
Study: 12737246

Group type: EXPERIMENTAL
Intervention: In-Ceram Alumina FPDs
Number of subjects: 37
Study: 10679652

Group type: EXPERIMENTAL
Intervention: 160 mg/day megestrol acetate (low dose)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 640 mg/day megestrol acetate (high dose)
Number of subjects: 149